Phenserine

Drug Profile

Phenserine

Alternative Names: DWJ301; Phenserine tartrate

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA)
  • Developer Cenomed BioSciences; Daewoong Pharmaceutical; QR Pharma
  • Class Neuroprotectants; Nootropics; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein precursor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Poisoning
  • Discontinued Cognition disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Poisoning in USA (PO)
  • 03 Nov 2009 Discontinued - Clinical-Phase-Unknown for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top